Genetic Determinants of Warfarin Anticoagulation Effect
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The response to warfarin varies greatly among individuals. Some of this variability can be
ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the
metabolism of S warfarin. In addition genetic polymorphism in other genes (i.e. VKORC1,
factor VII) have been shown to account for some of the variability in the response to
warfarin irrespective of CYP2C9.The present study has several segments:
1. Evaluation of the relationship between genetic polymorphisms in the genes encoding for
CYP2C9, VKORC1 and factor VII and warfarin maintenance dose at steady state. This study
is a confirmation of previous data in our own population.
2. Evaluation of relationship between genetic polymorphisms in the genes encoding for
CYP2C9, VKORC1 and factor VII and warfarin loading dose during the induction period.
3. Testing the hypothesis that warfarin loading based on the individual's combined CYP2C9,
VKORC1 and factor VII genotype may be more efficient and associated with reduced adverse
drug effects.
Phase:
N/A
Details
Lead Sponsor:
Hadassah Medical Organization
Collaborators:
Israel Science Foundation Ministry of Health, Israel United States - Israel Binational Science Foundation